INCY News and Press, Incyte Corporation From 10/10/23

MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, t...

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add...

2023-09-20 14:15:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Federal Reserve’s decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on. That...

2023-09-19 12:25:41 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 19, 2023 – USA News Group –  A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding f...

2023-09-18 10:52:04 ET Summary Incyte's Q2 2023 revenue rose to $955M, driven by strong sales of Jakafi and a surging Opzelura, but offset by rising R&D costs. Solid liquidity position with $3.4B in cash allows strategic R&D investment; upcoming Phase II data on pipeline c...

2023-09-13 10:25:54 ET More on AbCellera, Incyte, etc. AbCellera Biologics Inc. ( ABCL ) Q2 2023 Earnings Call Transcript AbCellera Biologics Inc. 2023 Q2 - Results - Earnings Call Presentation Incyte Corporation ( INCY ) Q2 2023 Earnings Call Transcript ...

2023-09-08 15:09:33 ET More on Briacell Seeking Alpha’s Quant Rating on Briacell Therapeutics Historical earnings data for Briacell Therapeutics Financial information for Briacell Therapeutics For further details see: BriaCell falls after Phase 2 d...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-14 17:28:47 ET Summary Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of 2023. The cutaneous squamous cell carcinoma treatment mar...

2023-08-06 17:35:15 ET More on the markets Charts Say Pullback Should Be Followed By Higher Highs SPY: It's Time To Book Some Profits (Technical Analysis, Rating Downgrade) 3 Reasons Why SPY Could Be On The Cusp Of A Bear Market Roth MKM still sees recession ...